top of page

Have you or a loved one been diagnosed with mild to moderate Alzheimer’s  Dementia?  A new Hackensack University Medical Center  human clinical study is currently underway.

ENROLLMENT IS LIMITED

Hackensack University Medical Center in New Jersey has started a new simple, at-home treatment with a safe, innovative device, to evaluate its impact on slowing or halting the progression of mild to moderate Alzheimer's Dementia.

The clinical study is taking place at Hackensack University Medical Center and Jersey Shore University Medical Center.

An initial brain cell study utilizing a proprietary new electrotherapy was recently completed at the University of New Mexico and was shown to significantly reduce inflammation by altering the levels of proteins that control the inflammatory process, which many scientists believe plays a critical role in Alzheimer’s Dementia.

A simple, headband-type medical device is worn two to three times per day for 15 minutes - in the comfort of your own home.


Enrollment is limited so click here to sign up today or call 551ADSTUDY (551-237-8839), for more information.
ENROLLMENT IS LIMITED
Alzheimer's Dementia

Frequently Asked Questions

Why should I take part in this study?

This clinical study will show what, if any, positive effects that a Pulsed Electromagnetic Field (PEMF) treatment via a new innovative non-invasive wearable device will have on your Alzheimer’s Dementia. PEMF therapy devices use a therapeutic electrical field to target cells and tissues.


What risks are involved in participating in this study?
No
known risks are associated with the treatment delivered by the ECHS™ device if used as instructed. Similar devices are used successfully to treat other conditions and this study is being done to see what effects it has on Alzheimer's Dementia. The device in this study produces a low-power electrical field. This electrical field is less powerful than the electrical field produced by a cell phone. The Institutional Review Board (IRB) for the study determined that the device is a non-significant risk (NSR) device.

When does the study start?
The six-month (180-day) treatment protocol is currently underway. The study only requires in-person visits every 45 days for 180 days. Reach out soon as enrollment is limited.

ENROLLMENT IS LIMITED
FAQ
Alzheimer's By the Numbers

7 Million +

Americans are living with Alzheimer's or another form of Dementia

1 in 3

Seniors die with
Alzheimer’s or another form of Dementia

bottom of page